Multiple sclerosis and cancer treatments have driven growth in Merck’s life science business, but the company downgrades its full-year profit forecast, now targeting growth of roughly 2-7%.
发布者:BY ULRICH QUISTGAARD,转转请注明出处:https://robotalks.cn/merck-downgrades-earnings-guidance-due-to-geopolitical-turmoil/